real-time news and commentary for investors
Monday, Nov 26
2012, 1:34 PM
EntreMed (ENMD +23.7%) soars today after reporting positive results from preclinical breast...
EntreMed (ENMD +23.7%) soars today after reporting positive results from preclinical breast cancer studies of its oral Aurora A/angiogenic kinase inhibitor, ENMD-2076. Results indicated that the drug exhibited robust anticancer activity against a particularly difficult to treat subtype called "triple-negative" breast cancer. The data provides the basis for a predictive biomarker strategy to explore in future clinical trials.